Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 23;24(18):4380–4387. doi: 10.1158/1078-0432.CCR-18-0613

Table 2.

Overview of AEs in the safety population

AE, n (%) All patients
(N = 60)
Any-grade AEs 60 (100.0)
Grade ≥3 AEs 30 (50.0)
Grade 5 AEs 4 (6.7)
Serious AEs 19 (31.7)
AEs leading to taselisib dose modifications
  AE leading to taselisib dose reduction 14 (23.3)
  AE leading to taselisib dose interruption 27 (45.0)
  AE leading to taselisib discontinuation 12 (20.0)